Star Lake Bioscience: Profit Soars, Growth Plan on Track

Star Lake Bioscience announced a robust performance in the first half of 2025, with net profit attributable to shareholders increasing by 65.22%. The company reported operating revenue of 8,159,559,845.57 yuan, a slight decrease of 3.85% year-on-year, primarily due to falling market prices for its main products. Despite this, total profit surged by 60.77% to 1,042,136,714.03 yuan, driven by optimized internal management, enhanced operational efficiency, and reduced raw material procurement costs.

The company is actively pursuing strategic expansion, with the board of directors approving a 3.3 bn yuan investment for a 450,000-ton amino acid project in Daqing, Heilongjiang province. Additionally, the 3.712 bn yuan 600,000-ton corn deep processing and co-generation project in Xinjiang province, approved in 2024, is progressing as planned, with over 1.3 bn yuan invested to date.

In related governance news, the supervisory board approved the 2025 semi-annual report and re-appointed Tianjian Certified Public Accountants (Special General Partnership) as its audit firm for 2025, with an audit fee not exceeding 2.4 m yuan. The board also decided to cancel the supervisory board and amend the company's articles of association and other governance documents.